Researchers at the School of Medicine and the UVA Biocomplexity Institute have been selected to help establish a national pathogen genomics surveillance network.
A genomic test being developed by a Charlottesville company can predict a patient’s risk of developing severe COVID-19, new research from UVA Health suggests. That information could help doctors identify patients at high risk for poor outcomes and quickly begin tailored treatment.
A monoclonal antibody used to treat asthma and eczema can improve survival for patients with moderate to severe COVID-19, a clinical trial at UVA Health suggests.
With scientists counting on our immune systems’ “memory” to provide long-term protection against severe COVID-19, School of Medicine researchers and their collaborators have shed light on how one such type of “memory” cells mounts powerful defenses against subsequent infections.